ESTRO 2022 - Abstract Book

S81

Abstract book

ESTRO 2022

Conclusion Delivery of a focal boost with moderate hypofractionation is feasible and effective, with CRO and PRO toxicity data comparable to contemporary series without a boost. However, incidence of GU toxicity now has predominance over GI toxicity. The efficacy of a DIL boost using the same dose +/- pelvic RT is under investigation in the UK randomised phase III trial, PIVOTALboost (ISRCTN80146950).

Proffered Papers: Upper GI

OC-0107 Randomised phase 2 trial of preop chemo(radio)therapy in gastric cancer: CRITICS-II interim results

M. Verheij 1,2 , A.E. Slagter 1 , E.P. Jansen 1 , H.W. van Laarhoven 3 , A. Cats 4 , J. van Sandick 5 , N.C. van Grieken 6 , P. Muller 7 , K. Sikorska 7 1 Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands; 2 Radboud University Medical Center, Radiation Oncology, Nijmegen, The Netherlands; 3 Amsterdam UMC, Medical Oncology, Amsterdam, The Netherlands; 4 Netherlands Cancer Institute, Gastrointestinal Oncology, Amsterdam, The Netherlands; 5 Netherlands Cancer Institute, Surgical Oncology, Amsterdam, The Netherlands; 6 Amsterdam UMC, Pathology, Amsterdam, The Netherlands; 7 Netherlands Cancer Institute, Biometrics, Amsterdam, The Netherlands Purpose or Objective Perioperative chemotherapy (CT) and postoperative chemoradiotherapy (CRT) are standard treatment options for locally advanced resectable gastric cancer. From the CRITICS and other studies it is known that these multimodality regimens are associated with poor patient tolerability, especially in the postoperative phase. The CRITICS-II trial was designed to identify